Sign In
Last checked at 
7 Dec 2020 07:00
genedrive plc
("genedrive" or the "Company")
Additional Listing of Shares
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that 9,711 new ordinary shares of 1.5p each in the Company ('New Ordinary Shares') have been issued to former employees pursuant to the rules of the Epistem Share Investment Plan.
Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 11 December 2020. The New Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.
Following admission, the Company's issued share capital will comprise 56,474,463 Ordinary Shares with voting rights ('Shares'). No Shares are held in Treasury. As such, the number of Shares with voting rights is 56,474,463. This figure may be used by shareholders (and others with notifiable obligations) as their denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
For further details please contact:
genedrive plc | www.genedriveplc.com | |
David Budd: CEO / Matthew Fowler: CFO | +44 (0)161 989 0245 | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 | |
James Steel / Oliver Jackson | ||
finnCap (Joint Broker) | +44 (0)20 7220 0500 | |
Geoff Nash / Kate Bannatyne / Alice Lane | ||
Walbrook PR Ltd (Media Relations & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com | |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 | |
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID kit has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. The Company has assays on market for the detection of certain biological targets and has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).
Further details can be found at: www.genedriveplc.com and www.genedrive.com.
Follow the stocks
